May 8 (Reuters) - German chemicals group Evonik Industries on Wednesday forecast its core profit for the second quarter to be "roughly on par" with that of the first quarter.

The company said its first-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at 522 million euros ($560.63 million), in line with preliminary figures published last month, and reiterated its full-year 2024 outlook.

"Many of our customers are buying again," Evonik chief executive Christian Kullmann said in a statement, but added that there was no broad-based upturn yet, as some industries and markets remained restrained.

Evonik's chemicals are used in products from cars to animal feed, as well as in Pfizer and BioNTech's COVID vaccine. ($1 = 0.9311 euros) (Reporting by Anastasiia Kozlova and Amir Orusov. Editing by Gerry Doyle)